A randomized cross-over trial to determine the effect of Cremophor EL on the pharmacodynamics and pharmacokinetics of carboplatin chemotherapy

详细信息    查看全文

• 作者：Sherene Loi ; Danny Rischin ; Michael Michael ; Kally Yuen ; Kerrie H. Stokes ; Andrew G. Ellis ; Michael J. Millward and Lorraine K. Webster
• 关键词：Cremophor EL ; Carboplatin ; Pharmacokinetics/dynamics ; Platelet sparing ; Myelosuppression
• 刊名：Cancer Chemotherapy and Pharmacology
• 出版年：2004
• 出版时间：November 2004
• 年：2004
• 卷：54
• 期：5
• 页码：407-414
• 全文大小：240 KB
• 刊物类别：Biomedical and Life Sciences
• 刊物主题：Biomedicine
  Cancer Research
  Pharmacology and Toxicology
  Oncology
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1432-0843

文摘

Purpose Paclitaxel, when combined with carboplatin, exhibits a platelet-sparing effect. Paclitaxel is formulated in Cremophor EL (CrEL), which has been shown in preclinical models to reduce haematological toxicity from radiotherapy and chemotherapy. We sought to determine the effect of a 3-h infusion of 20 ml/m2 (equivalent to 175 mg/m2 paclitaxel) CrEL on myelosuppression following carboplatin chemotherapy, and the effect of CrEL on carboplatin pharmacokinetics.